Osteoporosis in men is a public health problem. Although many studies have assessed epidemiology, pathophysiology, and clinical aspects of the osteoporosis in men, a lot of questions have not been answered, for example, bone mineral density measured by DXA identifies 20% of men at risk of fracture. We need more studies on the identification of men at high risk for fracture. Less frequent diseases also contribute to the overall burden of the osteoporosis in men, for example, idiopathic osteoporosis, idiopathic hypercalciuria, and so forth.

Our aim is to address current unmet needs regarding epidemiology, pathogenesis, diagnosis, and treatment of the osteoporosis in men. We invite authors to present original research and review manuscripts on the current state of knowledge on this subject. The manuscripts should stimulate the efforts in the understanding of mechanisms of the osteoporosis in men and in improving its management in the clinical practice. We expect manuscripts concerning not only the aging-related osteoporosis in older men but also osteoporosis related to less frequent diseases, for example, hypogonadism, idiopathic hypercalciuria, mastocytosis, haemochromatosis, idiopathic osteoporosis, and so forth. Of particular interest are studies concerning the societal and financial burden of the osteoporotic fractures in men in various countries. Other topics include, but are not limited to:

• Lifestyle factors associated with higher risk of falls and fractures
• Diseases associated with higher risk of fracture in men, for example, chronic obstructive pulmonary disease, HIV infection, organ transplantation, and so on
• Medications which increase the fracture risk, for instance, selective serotonin re-uptake inhibitors, proton pump inhibitors, and thiazolidinediones
• Pathophysiologic mechanisms of the idiopathic osteoporosis in men
• Pathophysiologic mechanisms inducing secondary osteoporosis in men with idiopathic hypercalciuria, haemochromatosis, mastocytosis, and so forth
• Pathophysiologic mechanisms of bone fragility including hormonal mechanisms and abnormal metabolism of bone proteins (e.g., formation of cross-links or aging-related glycation end products)
• Improvement of the identification of men at high risk for fracture (clinical scores, macro- and microarchitectural parameters, biological markers, hormones, and cytokines)
• Structural determinants of bone fragility in men (macro- and microarchitecture, bone mineral, and bone proteins)
• Better identification of the infrequent causes of the secondary osteoporosis in the osteoporotic men, that is, in men presenting fragility fracture or incidentally found low bone mineral density